Mesenchymal stem cells modified with a single-chain antibody against EGFRvIII successfully inhibit the growth of human xenograft malignant glioma.
Glioblastoma multiforme is the most lethal brain tumor with limited therapeutic options. Antigens expressed on the surface of malignant cells are potential targets for antibody-mediated gene/drug delivery.In this study, we investigated the ability of genetically modified human mesenchymal stem cells...
Main Authors: | Irina V Balyasnikova, Sherise D Ferguson, Sadhak Sengupta, Yu Han, Maciej S Lesniak |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2010-03-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC2841188?pdf=render |
Similar Items
-
Development of an EGFRvIII specific recombinant antibody
by: Li Gordon, et al.
Published: (2010-10-01) -
Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
by: Ayguen Sahin, et al.
Published: (2018-01-01) -
EGFRvIII: An Oncogene with Ambiguous Role
by: Adrianna Rutkowska, et al.
Published: (2019-01-01) -
The natural history of EGFR and EGFRvIII in glioblastoma patients
by: Shi Weiming, et al.
Published: (2005-10-01) -
Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited
by: Nicola Montano, et al.
Published: (2011-12-01)